Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from AbbVie ( (ABBV) ) is now available.
On September 11, 2025, AbbVie announced a settlement with all generic manufacturers regarding the generic versions of its drug RINVOQ, delaying generic entry in the U.S. until April 2037, assuming pediatric exclusivity is granted. This settlement potentially strengthens AbbVie’s market position by extending its exclusivity period, impacting stakeholders by delaying generic competition and maintaining market share for RINVOQ.
The most recent analyst rating on (ABBV) stock is a Hold with a $228.00 price target. To see the full list of analyst forecasts on AbbVie stock, see the ABBV Stock Forecast page.
Spark’s Take on ABBV Stock
According to Spark, TipRanks’ AI Analyst, ABBV is a Neutral.
AbbVie’s strong earnings performance and positive technical indicators are offset by valuation concerns and financial leverage risks. The raised guidance and strategic R&D investments provide a positive outlook, but the high P/E ratio and negative equity require caution.
To see Spark’s full report on ABBV stock, click here.
More about AbbVie
AbbVie is a biopharmaceutical company that focuses on developing and marketing advanced therapies for complex and serious health conditions. Its primary products include pharmaceuticals, with a strong emphasis on immunology, oncology, virology, and neuroscience.
Average Trading Volume: 5,477,944
Technical Sentiment Signal: Buy
Current Market Cap: $373.9B
See more data about ABBV stock on TipRanks’ Stock Analysis page.